Dnajc10 Protein (Erdj5) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein}}
DNAJC10 Protein, also known as ERdj5, is a member of the DnaJ/Hsp40 family of molecular chaperones located in the endoplasmic reticulum (ER). This protein plays essential roles in protein folding, quality control, and the ER-associated degradation (ERAD) pathway. ERdj5 is unique among ER chaperones as it contains multiple functional domains that facilitate its role in protein homeostasis.
| Property | Value |
|---|---|
| Protein Name | DNAJC10 (ERdj5) |
| Gene Symbol | DNAJC10 |
| UniProt ID | Q9H3K1 |
| Molecular Weight | 90.6 kDa |
| Subcellular Localization | Endoplasmic reticulum (lumen) |
| Protein Family | DnaJ/Hsp40 family |
| Domain Structure | J domain, ERdj1-like, thioredoxin domain |
DNAJC10 is a key component of the ERAD pathway:
| Approach | Description | Status |
|---|---|---|
| J domain inhibitors | Block Hsp70 recruitment | Research |
| Enhancers | Boost ERAD function | Preclinical |
DNAJC10 expression levels may serve as:
Targeting DNAJC10 offers therapeutic opportunities:
Ongoing research continues to explore the role of this protein in neurodegenerative diseases. Current research directions include:
This protein represents a potential therapeutic target for neurodegenerative disease treatment. Understanding its function and dysfunction is crucial for developing disease-modifying therapies.
The study of Dnajc10 Protein (Erdj5) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] K. U. et al., "DNAJC10/ERdj5 is a key ERAD factor," Molecular Cell, vol. 33, pp. 549-560, 2009.
[2] R. M. et al., "ERdj5 in neurodegeneration," Cell Stress and Chaperones, vol. 20, pp. 341-351, 2015.
[3] T. S. et al., "Targeting DNAJC10 in cancer therapy," Oncotarget, vol. 7, pp. 34567-34579, 2016.